Immunology-based recommendations for available and upcoming biologics in aspirin-exacerbated respiratory disease

Kathleen M. Buchheit, MD, Tanya M. Laidlaw, MD, Joshua M. Levy, MD, MPH

PII: S0091-6749(21)00976-3
DOI: https://doi.org/10.1016/j.jaci.2021.06.019
Reference: YMAI 15176

To appear in: Journal of Allergy and Clinical Immunology

Received Date: 3 May 2021
Revised Date: 9 June 2021
Accepted Date: 16 June 2021

Please cite this article as: Buchheit KM, Laidlaw TM, Levy JM, Immunology-based recommendations for available and upcoming biologics in aspirin-exacerbated respiratory disease, Journal of Allergy and Clinical Immunology (2021), doi: https://doi.org/10.1016/j.jaci.2021.06.019.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.
Immunology-based recommendations for available and upcoming biologics in aspirin-exacerbated respiratory disease

Kathleen M. Buchheit, MD¹, Tanya M. Laidlaw, MD¹ and Joshua M. Levy, MD, MPH²

¹Department of Medicine, Harvard Medical School, the Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Massachusetts;
²Department of Otolaryngology – Head & Neck Surgery, Emory University, Atlanta Georgia.

Corresponding Author:
Kathleen M. Buchheit, MD
Brigham and Women’s Hospital
60 Fenwood Rd, Suite 5002H
Boston, MA 02445
Telephone:617-732-9850
Fax: 617-731-2748
Email: kbuchheit@bwh.harvard.edu

Funding: This work was supported by the National Institutes of Health (NIH grants U19AI095219, K23AI139352, R01HL128241), and by generous contributions from the Vinik and Kaye Families.

Conflict of Interest: T Laidlaw has served on scientific advisory boards for GlaxoSmithKline and Sanofi-Genzyme, Optinose, AstraZeneca and Regeneron. K Buchheit has served on scientific advisory boards for AstraZeneca and GlaxoSmithKline. J Levy has served on scientific advisory boards for Regeneron Pharmaceuticals and GlaxoSmithKline.

Key Words: Aspirin-exacerbated respiratory disease, respiratory biologic, immunoglobulin E, interleukin 5, interleukin 5Rα, interleukin 4Rα, nasal polyp, mepolizumab, benralizumab, omalizumab, dupilumab
Aspirin-exacerbated respiratory disease (AERD) is characterized by severe chronic rhinosinusitis with nasal polyps (CRSwNP) and eosinophilic asthma. The upper and lower respiratory tract symptoms are notoriously difficult to treat, with many patients failing first-line therapies.\textsuperscript{1} The advent of targeted respiratory biologic medications offers promise for patients with AERD who have had inadequate response to prior standard-of-care approaches. However, there are limited data to guide selection of the proper respiratory biologic for AERD patients. Herein we discuss our understanding of the immunopathology of respiratory tract inflammation in AERD and how that may help guide biologic selection in this patient population.

Pathobiology of respiratory tract inflammation

AERD is predominantly a type 2 inflammatory disease characterized by marked tissue eosinophilia, activated mast cells and dysregulated production of cysteinyI leukotrienes and prostaglandins.\textsuperscript{1} More recently, a subendotype of AERD defined by type 1 and type 3 cytokines has also been identified.\textsuperscript{2} We now know the respiratory tract epithelium in nasal polyp tissue is also severely dysregulated, with basal cell hyperplasia and glandular cell reductions.\textsuperscript{3} Both intrinsic and extrinsic factors likely drive the epithelial dysregulation and overproduction of innate epithelial cell-derived type 2 cytokines, interleukin (IL)-33 and thymic stromal lymphopoietin (TSLP). Both IL-33 and TSLP are elevated in the respiratory tissue of patients with AERD and play a role in promoting eosinophilic inflammation and mast cell activation with consequent overproduction of prostaglandin D\textsubscript{2} and leukotrienes.\textsuperscript{1}

Group 2 innate lymphoid cells (ILC2s) and Th2 cells are abundant in polyp tissue, and along with mast cells, produce type 2 cytokines such as IL-4, IL-5, and IL-13 (Figure 1). IL-4 and IL-13 signal through the common IL-4Rα subunit to promote a number of effects, including tissue fibrosis and remodeling, goblet cell hyperplasia and mucus production, mast cell activation and survival, and local IgE class switching.\textsuperscript{1} Although AERD is not typically considered to be an atopic disease, a recent study identified a relationship between nasal polyp tissue IgE and rapidity of nasal polyp regrowth in patients with AERD, suggesting IgE as a marker of severe disease and perhaps as a driver of ongoing mast cell activation and respiratory tissue inflammation (Figure 1).\textsuperscript{4}

IL-5 is required for eosinophil survival and activation, but other cell types also express a functional IL-5Rα and recently a possible role for IL-5/IL-5Rα signaling on nasal polyp plasma
cells in patients with AERD has been identified. While much attention has been focused on the nasal polyp tissue eosinophilia that is prominent in AERD, complete depletion of eosinophils from the respiratory tissue with the small molecule dexpanipexole did not lead to symptomatic improvement or reduction in nasal polyposis, suggesting that eosinophils may not be the main effector cell that drives the chronic inflammation.

**Targeted therapy with respiratory biologic medications in AERD**

Increased understanding of the immunobiology of CRSwNP and asthma in AERD has resulted in the identification of several type 2 cytokines and cytokine receptors that may be targeted by available and upcoming biologics. Among these, dupilumab (anti-IL-4Rα and omalizumab (anti-IgE) have been specifically studied in patients with AERD, and both have U.S. Food and Drug Administration indications for the treatment of moderate-to-severe asthma, and as add-on therapy for inadequately controlled CRSwNP.

Dupilumab inhibits signaling of both IL-4 and IL-13, two pivotal drivers of type 2 inflammation (Figure 1). A nested analysis of 19 AERD patients receiving either dupilumab or placebo in a phase 2a, randomized controlled trial (NCT01920893) demonstrated improved upper and lower airway symptom control among those with AERD versus CRSwNP patients without NSAID sensitivity. Specific improvement was seen in the objective nasal polyp score (least-squares mean difference -2.51 versus placebo and -0.72 versus CRSwNP without NSAID sensitivity), as well as objective measures of mucosal inflammation and olfaction. Additionally, subjective improvement in asthma control, sinonasal symptoms and sense of smell/taste was found in CRSwNP patients with or without comorbid NSAID sensitivity.

Elevated IgE is found in nasal polyp tissues and is associated with increasing airway inflammation in AERD. Omalizumab is an anti-IgE biologic which may improve airway inflammation in AERD via direct reductions in eosinophil, basophil and mast cell activation (Figure 1). In a study of 21 AERD patients with comorbid aeroallergen sensitivity treated with omalizumab, Hayashi et al. demonstrated decreased biomarkers of mast cell activation (leukotriene E4 and a prostaglandin D2 metabolite) following twelve months of therapy. Patient symptoms also improved, with reductions in lower airway exacerbations, corticosteroid utilization, hospitalization and CRSwNP/asthma symptom scores.
Anti-IL-5/IL-5Rα biologics, which reduce local respiratory tissue eosinophilia in patients with CRSwNP and asthma, have shown promise in the treatment of severe asthma, and can be efficacious for upper respiratory symptoms in AERD. However, as isolated depletion of eosinophils does not provide symptomatic improvement or the reduction of obstructive nasal polyps, the mechanism of anti-IL-5 biologics in AERD patients may not be limited to its effects on eosinophils. Additional cellular mechanisms by which IL-5 blockade may provide benefit include decreased mast cell leukotriene E₄ production and improved function of the respiratory epithelial barrier (Figure 1), as shown in a recent case-control study of AERD patients treated with mepolizumab. Benralizumab (anti-IL-5Rα) and mepolizumab (anti-IL-5) are currently being evaluated for the treatment of CRSwNP. In a recently completed phase 3 study of mepolizumab for CRSwNP, a subgroup analysis of the subjects with co-morbid AERD showed greater improvement in the co-primary endpoints, nasal obstruction and nasal polyp size, in the mepolizumab-treated AERD subjects compared to placebo. Benralizumab has a current indication for severe eosinophilic asthma and its use for CRSwNP is supported by a subgroup analysis of a phase 3b clinical trial that demonstrated improved 22-item Sinonasal Outcome Test (SNOT-22) scores among n=153 subjects with comorbid CRSwNP (NCT03170271). While this field continues to emerge, early findings suggest that only a subset of patients with AERD have satisfactory clinical response to biologics targeting IL-5/IL-5Rα, and dupilumab may improve respiratory symptoms in AERD patients who have had an inadequate response to anti-IL-5/IL-5Rα biologics.

Monoclonal antibodies targeting IL-33 and TSLP are currently under investigation for treatment of asthma and/or CRSwNP (NCT03469934, NCT03112577, NCT03614923, NCT03706079). We look forward to studies of these biologics in patients with AERD, as both cytokines are significantly elevated in tissue from patients with AERD and likely have an important role in driving mast-cell mediated inflammation.

**Conclusion**

Targeted respiratory biologics represent a clinically significant advancement in our ability to improve treatment outcomes for recalcitrant, type 2 inflammatory diseases such as AERD. However, these immunomodulatory medications are very costly and many do not yet have long-term safety or outcome data available, and therefore are not required by nor
appropriate for all AERD patients. We therefore use the treatment pathway shown in Figure 2 to aid in decision making, and typically offer biologics only following comprehensive sinus surgery and a trial of aspirin desensitization. Future head-to-head studies and real-world evidence is needed to support personalized treatment strategies and the identification of the most efficacious biologic for a given patient.
References


Figure Legends:

**Figure 1:** Impact of IgE, IL-5, IL-5Rα, and IL-4Rα on type 2 inflammation in the upper and lower airway. IgE, IL-5, IL-5Rα, and IL-4Rα, which are the targets of currently available respiratory biologic medications, act on multiple cell types in the upper and lower airway including eosinophils, basophils, mast cells, epithelium, plasma cells, macrophages, and smooth muscle.

**Figure 2:** Proposed treatment algorithm for aspirin desensitization and targeted respiratory biologics for patients with AERD.
IL-5/IL5Rα
- Eosinophil
  - Recruitment, activation
  - Possible ↑ release of eosinophil peroxidase (EPO)

IL-4Rα
- Basophil
  - Survival, ↑ FcεRI expression
  - Activation, degranulation, mediator release

IL-5/IL5Rα
- Mast cell
  - ↑ LTE4 release
  - IgE priming, modulation of FcεRI, ↑ leukotriene production, ↑ proliferation
  - Survival, activation, degranulation, mediator release

IL-5/IL5Rα
- Respiratory Epithelium
  - Actions unknown; possible downregulation of adhesion molecules
  - ↑ Chemokine expression, ↑ mucous secretion, goblet cell metaplasia, epithelial barrier damage, ↓ ciliary function

IL-5/IL5Rα
- B cell/Plasma cell
  - Actions unknown; possible enhanced proliferation and survival
  - IgE production

IL-4Rα
- Smooth Muscle
  - ↑ Smooth muscle proliferation

IL-4Rα
- Macrophage/Monocyte
  - ↑ CD23 and MHC Class II expression, M2 polarization
Nasal polyp recurrence?  
Yes  
No  
Asthma sufficiently controlled? 
Yes  
No  
Asthma sufficiently controlled post-op? 
Yes  
No  
Sufficient symptom control? (well-controlled asthma & low burden of sinus symptoms) 
Yes  
No  
Initiate appropriate increase in medical therapy with encouraged compliance 
Review after 3 months 
Insufficient improvement 
Surgery 
Post-operative medical care with sinus irrigation and topical steroids 
Review after 1-3 months 
Sufficient improvement 
Recommend ASA desensitization / high-dose ASA therapy (to prevent nasal polyp growth and allow use of other NSAIDS) 
Continue topical steroids, sinus irrigation, asthma management, daily ASA; review every 3-6 months 
Nasal polyp recurrence?  
Yes  
No  
Asthma sufficiently controlled?  
Yes  
No  
Initiate biologic; review every 6 months; continue biologic if efficacious